A Phase I, Multicenter, Randomized, 12-Week, Open-Label Study to Evaluate the Multiple Dose Pharmacokinetics and Pharmacodynamics of RPC 1063 in Patients With Relapsing Multiple Sclerosis
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 17 Jun 2017
At a glance
- Drugs Ozanimod (Primary)
- Indications Multiple sclerosis
- Focus Pharmacokinetics
- Sponsors Celgene Corporation
- 12 Jun 2017 Planned End Date changed from 1 Apr 2017 to 31 Dec 2017.
- 12 Jun 2017 Planned primary completion date changed from 1 Mar 2017 to 31 Dec 2017.
- 12 Jun 2017 Status changed from recruiting to active, no longer recruiting.